AgeX Therapeutics (AGE)
(Delayed Data from AMEX)
$NA USD
0 (0.00%)
Updated Dec 31, 1969 06:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for AgeX Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 1 | 1 | 1 | 2 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 2 | 2 | 1 | 1 |
Total Current Assets | 1 | 2 | 2 | 2 | 4 |
Net Property & Equipment | NA | 0 | 0 | 0 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 11 | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 2 | 2 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 12 | 3 | 3 | 4 | 7 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 1 | 1 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 9 | 8 | 4 | 1 |
Total Current Liabilities | 6 | 10 | 9 | 5 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 10 | 6 | 4 | 2 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 7 | 21 | 15 | 9 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | 136 | 99 | 94 | 92 | 88 |
Retained Earnings | -131 | -116 | -106 | -97 | -86 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | -17 | -12 | -5 | 3 |
Total Liabilities & Shareholder's Equity | 12 | 3 | 3 | 4 | 7 |
Total Common Equity | 100,004 | -17 | -12 | -5 | 3 |
Shares Outstanding | 1.08 | 1.08 | 1.00 | 1.00 | 1.00 |
Book Value Per Share | 92,596.63 | -16.04 | -11.88 | -5.40 | 2.62 |
Fiscal Year End for AgeX Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 0 | 0 | 0 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 2 |
Total Current Assets | 1 | 1 | 1 | 2 | 2 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 11 | 10 | 10 | 10 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 1 | 1 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 12 | 12 | 12 | 13 | 3 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 2 | 24 | 21 | 9 |
Total Current Liabilities | 6 | 3 | 25 | 23 | 10 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 10 | 10 | 10 | |
Minority Interest (Liabilities) | NA | 36 | 0 | 0 | 0 |
Total Liabilities | 7 | 40 | 35 | 33 | 21 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | 136 | 100 | 100 | 100 | 99 |
Retained Earnings | -131 | -128 | -122 | -119 | -116 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 5 | -28 | -22 | -20 | -17 |
Total Liabilities & Shareholder's Equity | 12 | 12 | 12 | 13 | 3 |
Total Common Equity | 100,004 | -28 | -22 | -20 | -17 |
Shares Outstanding | 1.08 | 1.08 | 1.00 | 1.00 | 1.00 |
Book Value Per Share | 92,596.63 | -25.60 | -22.30 | -20.01 | -17.32 |